In This Article:
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings tomorrow morning. Here’s what investors should know.
NeoGenomics missed analysts’ revenue expectations by 1% last quarter, reporting revenues of $172 million, up 10.6% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts’ EPS estimates.
Is NeoGenomics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting NeoGenomics’s revenue to grow 9.4% year on year to $170.9 million, slowing from the 13.9% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.01 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. NeoGenomics has missed Wall Street’s revenue estimates three times over the last two years.
Looking at NeoGenomics’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 12.1%, beating analysts’ expectations by 1.3%, and Centene reported revenues up 15.4%, topping estimates by 8.3%. Quest traded up 7.2% following the results.
Read our full analysis of Quest’s results here and Centene’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.6% on average over the last month. NeoGenomics is up 2.8% during the same time and is heading into earnings with an average analyst price target of $18.27 (compared to the current share price of $9.76).
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.